2026Year4Month20Day,ChinaGlobal medical technology giant Medtronic (NYSE:MDT) officially announced the completion of the acquisition of CathWorks, an AI-driven cardiac technology developer.CathWorksThe acquisition, transaction value5.85Billion US dollars（Equivalent to RMB40100 million)。This acquisition continues Medtronic's strategic expansion in the cardiovascular field, aiming to revolutionize coronary artery disease through innovative technologies (CAD) Diagnosis and Treatment Pathway.

Medtronic andCathWorksThe cooperation can be traced back to2018Year —— at that time, Medtronic already heldCathWorksMinority interest.2022In the year, the two parties established a strategic partnership, and Medtronic committed to investing.7500Million USD and Joint PromotionCathWorksTheFFRangioSystem.In addition,Both parties this year2Monthly Achievement of Acquisition Agreement。

CathWorksTheFFRangioThe system, based on artificial intelligence and advanced computing science, can analyze conventional angiography (XLight) Rapid generation of reliable fractional flow reserve (FFR) value, compared with traditional invasiveFFREvaluation (requires pressure wire, pharmacological hyperemia, and intravascular single-point measurement) creates a differentiated advantage.

CathWorksCEO Ramin Musavi stated, "This acquisition marks a redefinition of the future of cardiovascular care. Our long-term collaboration with Medtronic has yielded significant results, and this transaction reaffirms our shared commitment to revolutionizing catheterization labs and improving patient outcomes."

Senior Vice President of Medtronic Coronary and Renal Denervation BusinessJason WeidmanEmphasized: "FFRangioThe system will significantly enhance Medtronic's interventional cardiology product portfolio, accelerating patient access to transformative technologies through a global network.

Executive Vice President of Medtronic CardiovascularSkip Kiil"This acquisition is a model of Medtronic's strategic 'absorption' acquisitions, propelling the company to the forefront of cardiovascular digital transformation and providing next-generation solutions for doctors and patients."

CathWorksis a medical technology company headquartered in Kfar Saba, Israel.Founded in2013Year. The company focuses on developing cardiovascular imaging and treatment solutions based on computer vision and artificial intelligence technology, committed to advancing percutaneous coronary intervention (PCI) Provide objective data for decision-making, and elevate coronary angiography from visual assessment to a basis ofFFR(Flow Reserve Score) Decision Tool.

CathWorksActive in financing, having completed multiple rounds of funding with a total amount exceeding1.5Billion dollars. Its investors includeDeerfield Management、Triventures、Quark VentureAnd other well-known venture capital institutions.2022Year, Medtronic andCathWorksEstablish strategic partnerships, invest7500Million US dollars, and obtainCathWorks FFRangioThe system's market promotion rights in the United States, Europe, and Japan. In addition, Medtronic also owns2027Year7The highest level a month ago5.85Billion-dollar acquisitionCathWorksThe right to choose. This time, Medtronic also made the acquisition based on this right.

CathWorksThe core product isFFRangioSystem, this is a non-invasive coronary artery function assessment platform based on artificial intelligence and advanced computational science. The system has the following characteristics:

• Non-invasive:FFRangioThe system through conventional coronary angiography (XLight) to obtain physiological information, without the use of invasive pressure lines or drug stimulation, thereby reducing the patient's risk and discomfort.

• 3D Reconstruction: The system is able to2DAngiography converted to precise3DCoronary Artery Tree Model, Providing Comprehensive Vascular Anatomical Information.

• Real-time Hemodynamic Assessment:FFRangioThe system can calculate each point of the coronary artery tree in real time.FFRValue, helping doctors assess the physiological impact of coronary artery stenosis, thereby making more accurate diagnostic and treatment decisions.

• Optimize Clinical Decision-Making: The system provides physiological impact assessment of lesion treatment and interactive dimensional measurement tools, supporting physicians in making confident, patient-centered treatment decisions.

• High diagnostic accuracy: Multiple clinical studies have shown,FFRangioThe system has extremely high diagnostic accuracy, comparable to pressure-wire basedFFRThe measurement results are highly consistent.

FFRangioThe system workflow includes:

• Data Collection: The system based on an artificial intelligence platform will routinely2DAngiography converted to precise numbers of coronary artery tree3DModel.

• Hemodynamic Analysis: Evaluating occlusions through advanced algorithms,3D QCA(Quantitative Coronary Angiography) and flow resistance along each vessel.

• FFRValue Calculation: Using validated scientific principles, rapid pressure flow analysis calculates each point of the coronary artery tree.FFRValue, identify the parts that may require intervention.

• Result Display: The system generates a colored mapping grid, showing each location'sFFRValue, helping doctors intuitively understand the physiological condition of the coronary arteries.

FFRangioThe system has been approved by the U.S. Food and Drug Administration (FDA) of510(k)License, Israel Ministry of Health (Amar) Approval, Pharmaceuticals and Medical Devices Agency (PMDA) approved, and meet EUCERequirements for the Logo。

CathWorksActively PromoteFFRangioSystematic clinical research to verify its safety and effectiveness. For example,ALL-RISEThe study was conducted in the United States, Asia, Europe, and the Middle East.59Central Enrollment1924A randomized controlled trial of patients, aimed at evaluatingFFRangioClinical and economic benefits in the diagnosis and treatment of coronary artery disease. The results of this study are expected to redefine the standard of care for the assessment of coronary physiology.

This acquisition further solidifies Medtronic's leadership position in the cardiovascular field, while reflecting the ongoing investment trend in AI-driven diagnostic tools within the medical technology industry. Through integrationCathWorksTechnology, MedtronicHowEfficiency Improvement and Cost Optimization in the Diagnosis and Treatment of Coronary Heart Disease? Instrument Family will continue to follow up.